| Name | Title | Contact Details |
|---|---|---|
Wayne Berryman |
Assistant Director Information Security | Profile |
Anand Pattabiraman |
Senior Director of Information Systems | Profile |
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
MANUFACTURING Philosophy The TRC team understands that the actions required to be a successful pharmaceutical manufacturer are more than just completing repetitive and highly detailed tasks accurately; it is the understanding that we...
Our dedication to small, one- or two-dentist practices sets us apart from large, impersonal dental management companies. You’ll never see Cherry Tree Dental’s name on the building or ten doctors at one office. We value established, family practices, hi...
OutcomesMTM is a West Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Teva Canada is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.